
Five men, five separate families, one broken gene — and every one of them got an aggressive, spreading prostate cancer decades before doctors would expect it.
Quick Take
- Researchers found five unrelated men carrying an inherited, broken copy of a gene called CDK12 among 4,535 men with aggressive prostate cancer.
- All five developed cancer that spread to other parts of the body between ages 44 and 62, far younger than typical.
- The mutation shows up in roughly one of every 1,000 men with aggressive prostate cancer, a rare but real pattern.
- Scientists want CDK12 added to genetic testing panels for men and families who already qualify for hereditary cancer screening.
A Gene Nobody Was Watching Closely
Researchers at the University of Washington School of Medicine sequenced tumor samples from 4,535 men battling aggressive prostate cancer. They compared those tumor results against DNA pulled from the men’s normal, non-cancerous blood cells. Five men stood out. Each carried one healthy copy of the CDK12 gene and one copy that was broken from birth, passed down through their families.
That might sound like a small detail buried in a lab report. It isn’t. CDK12 helps repair damaged DNA inside cells. When both copies of the gene fail, the body loses a key defense against cancer-causing mutations. Finding five men who inherited a damaged copy, and then watched their cancer take off young, is the kind of signal cancer researchers spend careers chasing.
Young, Aggressive, and Spreading Fast
Every one of the five carriers developed metastatic prostate cancer, meaning it had already spread, somewhere between age 44 and 62. That is strikingly young. Most prostate cancer diagnoses happen well into a man’s late 60s or 70s, and metastatic disease at diagnosis is uncommon at any age. A cluster of young, aggressive cases tied to the same inherited gene defect is exactly the pattern doctors look for when hunting a hereditary cancer syndrome.
The tumor samples backed up the blood findings. In each carrier, the cancer cells showed damage to their remaining healthy copy of CDK12, matching the classic two-hit pattern scientists expect when an inherited gene defect sets the stage and a second mutation finishes the job. Researchers at the Terry Fox Research Institute, who helped fund the work, confirmed the tumors carried a distinct molecular fingerprint tied to CDK12 loss.
Why One In A Thousand Still Matters
About one in every 1,000 men with aggressive prostate cancer in the study carried this inherited CDK12 defect. That is a small slice. But prostate cancer strikes roughly one in eight American men over a lifetime, and aggressive cases number in the tens of thousands each year. Even a rare hereditary driver, once confirmed, touches real families who deserve to know their risk and plan accordingly.
Researchers behind the study recommended adding CDK12 to hereditary cancer-risk testing panels for patients who already meet existing screening guidelines based on personal or family cancer history. Those guidelines currently flag genes like BRCA1, BRCA2, ATM, CHEK2, and HOXB13 as prostate cancer risk factors, and CDK12 would join that list if clinical bodies adopt the recommendation.
What Still Needs Answering
The University of Washington team was careful to note that more work is needed before doctors can issue specific screening recommendations for men who test positive for the inherited mutation. That is a reasonable, honest limit on a fresh discovery, not a reason to doubt what the researchers found in their data.
Genetic discoveries like this one follow a familiar path. Scientists spot a pattern in affected patients, confirm it at the molecular level, then push for larger studies that measure exactly how much risk the gene carries and whether early screening saves lives. CDK12 now joins that pipeline, backed by real tumor data and five documented family cases rather than speculation.
Sources:
sciencedaily.com, pmc.ncbi.nlm.nih.gov, dailybeirut.com













